Immatics N.V. (IMTX)
| Market Cap | 663.06M |
| Revenue (ttm) | 18.45M |
| Net Income (ttm) | -35.20M |
| Shares Out | 17.97M |
| EPS (ttm) | -27.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $10.43 |
| Previous Close | $10.36 |
| Change ($) | 0.07 |
| Change (%) | 0.68% |
| Day's Open | 10.37 |
| Day's Range | 10.30 - 10.74 |
| Day's Volume | 242,175 |
| 52-Week Range | 8.66 - 17.25 |
News
There are no news available yet.
About IMTX
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets... [Read more...]
| Industry Biotechnology | |
| CEO Dr. Harpreet Singh | Employees 230 |
| Stock Exchange NASDAQ | Ticker Symbol IMTX |
Financial Performance
In 2019, Immatics's revenue was $18.45 million, an increase of 389.36% compared to the previous year's $3.77 million. Losses were -$31.57 million, 0.40% more than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for Immatics stock is "Strong Buy." The 12-month stock price forecast is 17.65, which is an increase of 69.22% from the latest price.